The research team followed 156 adults who developed invasive pneumococcal disease and required hospital care in Region Västra Götaland, Sweden, between 2018 and 2023. The median age of the patients was 70 years, a demographic in which both pneumococcal disease and blood malignancies become progressively more common. To determine whether the severe infection was merely bad luck or a signal of hidden vulnerability, the researchers performed detailed immunological workups. They measured antibody levels to detect deficiencies in humoral immunity, and they tested for the presence of M protein, a monoclonal immunoglobulin that serves as a well-established risk marker for blood cancer. A control group of 64 individuals, matched for age and sex but without invasive pneumococcal disease, provided a baseline for comparison.

The results were striking. Among the patients with invasive pneumococcal disease, one in four had M protein detectable in their blood. Monoclonal gammopathy of this kind can occur in established blood cancers, but it is also found in precursor states, conditions that do not yet meet the criteria for malignancy but can, in some patients, progress toward cancer over time. The examinations prompted by the study led to seven patients receiving a diagnosis of blood cancer, while another twelve were diagnosed with a precursor condition that may, in some cases, evolve into malignancy. In a group of just over 150 patients admitted for a severe bacterial infection, that represents a meaningful yield of previously silent disease.

The immune assessments also uncovered antibody deficiencies. Eight patients in the pneumococcal disease group were found to have immunodeficiency, and in seven of them, clinicians were able to start preventive treatment aimed at protecting against future severe infections. Such treatments can include replacement immunoglobulin therapy and tailored vaccination strategies, interventions that can substantially reduce the risk of recurrent invasive disease. By contrast, these abnormalities were considerably less common in the matched control group, reinforcing the idea that invasive pneumococcal infection is not randomly distributed but clusters in people whose immune surveillance is compromised.

The biological logic behind these findings is straightforward once the mechanics of pneumococcal immunity are considered. Streptococcus pneumoniae is an encapsulated bacterium, and its polysaccharide capsule is the principal target of protective antibodies. Clearance of the organism depends heavily on opsonization, the process by which antibodies coat the bacterium and mark it for destruction by phagocytic cells. People with low antibody levels, whether from a primary immunodeficiency or from the antibody-producing B-cell disorders that underlie many blood cancers, are therefore structurally less able to contain the bacterium when it colonizes the respiratory tract. What would be a mild or localized infection in an immunocompetent adult can become a systemic, hospital-requiring illness in someone whose humoral immunity is impaired.

M protein, the marker at the center of the study, is a monoclonal immunoglobulin produced by a single expanded clone of plasma cells or B cells. Its presence in the blood is the hallmark of a spectrum of disorders ranging from the benign-appearing monoclonal gammopathy of undetermined significance to smoldering and symptomatic myeloma. Because monoclonal gammopathies are common in older populations and often remain asymptomatic for years, most are discovered incidentally or not at all. The Gothenburg study suggests that severe pneumococcal disease may function as a clinical flag: when an older adult presents with invasive infection, the probability of finding an underlying monoclonal disorder is high enough that targeted testing could be worthwhile.

Currently, according to the researchers, these tests are not routinely performed after a severe pneumococcal infection. Tor Härnqvist, a doctoral student at the University of Gothenburg and an infectious disease physician at NU Hospital Group, and one of the lead authors of the study, points to the consequence of that gap. “Currently, these tests are not routinely performed after a severe pneumococcal infection. As a result, we may miss patients with undiagnosed blood cancer or immunodeficiency and therefore missing the opportunity to initiate treatment,” he says. The missed opportunity cuts in two directions: blood cancers such as myeloma are generally more treatable when identified before organ damage accumulates, and immunodeficiencies can be mitigated with preventive measures before the next invasive infection occurs.

The study carries implications for vaccination policy as well. Karin Bergman, a doctoral student in the same research group and an infectious disease physician at Södra Älvsborg Hospital, examined how the pneumococcal bacteria causing severe disease have shifted since the pneumococcal conjugate vaccine was introduced into the Swedish childhood vaccination program. Her analysis, part of a doctoral thesis she will soon defend at the University of Gothenburg, shows that the bacterial serotypes covered by the childhood vaccine have decreased sharply in circulation, but they have largely been replaced by other serotypes against which the childhood vaccine offers no protection. This serotype replacement is a well-documented ecological consequence of conjugate vaccination: eliminating vaccine-targeted strains from nasopharyngeal carriage opens ecological space for non-vaccine strains to colonize and spread.

Crucially, the serotypes now driving invasive disease in adults disproportionately affect older adults and individuals with underlying conditions, particularly cancer and compromised immune systems. This creates an uncomfortable alignment: the very populations most vulnerable to severe pneumococcal infection are those most likely to harbor undiagnosed blood cancer or antibody deficiency, and the circulating bacterial strains are precisely those that exploit gaps in adult immunity. “The results show that recommendations on pneumococcal vaccines for adults need to take into account which vaccines are used in children and which bacterial serotypes subsequently circulate in the community,” says Bergman. In other words, adult immunization strategy cannot be designed in isolation from the pediatric program, because the two are epidemiologically linked through the shifting serotype landscape.

Taken together, the findings support a concrete change in clinical practice. The researchers argue that screening for M proteins and antibody levels should be considered in adults who experience invasive pneumococcal disease, since the infection can reveal previously undiagnosed blood cancer and immunodeficiency. Such screening would involve relatively simple blood tests: quantitative measurement of serum immunoglobulins to identify antibody deficiencies, and protein electrophoresis or equivalent methods to detect monoclonal immunoglobulins. For a patient population that is already hospitalized and undergoing extensive workup, the incremental burden would be modest, while the potential benefit, catching a blood cancer or an immune deficiency that would otherwise remain hidden until it caused further harm, could be substantial. As populations age and serotype replacement continues to reshape pneumococcal epidemiology, the severe pneumonia that lands an older adult in the hospital may increasingly deserve to be read not only as an infection, but as a message from the immune system itself.

Subject of Research: Invasive pneumococcal disease as a marker of undiagnosed blood cancer and immunodeficiency in adults

Article Title: Pneumonia can reveal undiagnosed blood cancer

Article References: Pneumonia can reveal undiagnosed blood cancer. (n.d.). Original publication

Image Credits: AI Generated

DOI: Not provided

Keywords: pneumococcal disease, pneumonia, blood cancer, M protein, immunodeficiency, monoclonal gammopathy, Streptococcus pneumoniae, antibody deficiency, pneumococcal vaccine, serotype replacement, University of Gothenburg, Scientific Reports

The research team, led by Babak Pourakbari, Abolfazl Khalilianfard, Reihaneh Hosseinpour Sadeghi, Erfaneh Jafari, Shima Mahmoudi, and Setareh Mamishi, enrolled 195 children under 18 years of age who were admitted with respiratory symptoms between April 2023 and April 2024. The cohort comprised 129 boys and 66 girls, with a median age of 44 months and an interquartile range stretching from 7 to 78 months, meaning the study captured everything from infants in their first months of life to teenagers on the cusp of adulthood. None of the enrolled children had been vaccinated against pneumococcal disease, a circumstance that allowed the investigators to observe colonization patterns unshaped by vaccine-induced immune pressure. Nearly a quarter of the participants, 24.1 percent or 47 children, carried an underlying medical condition, a detail that would prove consequential as the analysis unfolded.

Methodologically, the study paired the traditional gold standard of bacterial culture with polymerase chain reaction, or PCR, a molecular technique that amplifies and detects specific DNA sequences. The researchers targeted the lytA gene, which encodes an autolysin found in pneumococci and is widely regarded as a highly specific genetic marker for the species. In parallel, they screened for the cpsB gene, which sits within the genetic machinery responsible for building the polysaccharide capsule, the slimy outer armor that distinguishes virulent, encapsulated strains from their naked counterparts. Demographic characteristics, underlying conditions, radiological findings, laboratory data, hospitalization history, antibiotic use, and vaccination status were all extracted from the children’s medical records, and the statistical analysis was performed in SPSS version 18.0 with a significance threshold set at a p-value below 0.05.

The headline result is a striking divergence between the two detection methods. Culture, the century-old workhorse of microbiology, identified S. pneumoniae in just 14 patients, a colonization prevalence of 7.2 percent. The lytA PCR, by contrast, flagged the organism in 60 patients, or 30.8 percent of the cohort, more than four times the culture figure. Every culture-positive sample was also positive by PCR, confirming that the molecular method subsumed rather than contradicted the conventional one. This gap is not merely a technical curiosity. It suggests that a large reservoir of pneumococcal DNA, and presumably of non-viable or difficult-to-culture organisms, lurks in the nasopharynx of symptomatic children in ways that standard laboratory workflows systematically miss, and it argues for a serious reconsideration of how carriage studies are designed and interpreted.

Perhaps the most biologically intriguing finding emerged from the cpsB screen. Of the 60 lytA PCR-positive samples, only 9, or 15 percent, carried the capsule gene. The overwhelming majority of detected pneumococci therefore appeared to be non-encapsulated strains. The capsule is the pneumococcus’s principal virulence factor, the molecular shield that allows it to evade phagocytosis by immune cells and to invade sterile sites such as the lungs, blood, and meninges. Strains lacking a capsule are generally considered less invasive and are often dismissed as commensal bystanders. A predominance of non-encapsulated organisms among PCR-positive children raises the possibility that much of what molecular testing detects in the nasopharynx represents relatively benign carriage rather than the capsule-bearing lineages most associated with invasive disease, a distinction with real implications for how clinicians weigh a positive PCR result.

The clinical correlates of colonization were equally informative. Pneumococcal detection was significantly more frequent among children with underlying medical conditions, with a p-value of 0.045, indicating that chronic illness creates fertile ground for the bacterium to take up residence. Children whose colonization was detected also showed abnormal findings on chest imaging more often than their colonization-negative peers, and their hospital stays were substantially longer, with a median of 9 days compared with 5 days for non-colonized children, a difference that was highly significant at p below 0.001. Colonization was most commonly observed among patients diagnosed with pneumonia and empyema, the latter being the accumulation of infected fluid in the pleural space surrounding the lungs, one of the most serious complications of bacterial pneumonia in childhood.

The authors are careful, and rightly so, to temper these associations with an important caveat. Nasopharyngeal detection of S. pneumoniae reflects colonization, not confirmed clinical infection. A child can carry the bacterium harmlessly while a virus or another pathogen drives the actual respiratory illness, and conversely, severe disease can alter the local environment of the airway in ways that favor pneumococcal growth. The longer hospital stays and abnormal imaging seen in colonized children may therefore be entangled with disease severity and other confounding factors rather than a direct causal effect of the pneumococcus itself. Disentangling innocent carriage from genuine pathogenic contribution remains one of the central challenges of pneumococcal research, and this study’s design, being cross-sectional, cannot by itself resolve that question.

Even with those limitations, the pre-vaccine context of the cohort gives the findings unusual scientific value. In countries with high pneumococcal conjugate vaccine coverage, the landscape of nasopharyngeal carriage has been fundamentally reshaped: vaccine-targeted serotypes are displaced, and non-vaccine serotypes, along with non-encapsulated strains, fill the ecological vacuum. Observing colonization in children who have never been vaccinated provides a baseline against which such vaccine effects can be measured, and the Tehran data suggest that even in that baseline state, non-encapsulated organisms constitute a large share of what molecular methods detect. This has implications for vaccine development, since current conjugate vaccines derive their protection from capsular polysaccharides and offer no direct coverage against strains that lack a capsule altogether.

The sensitivity gap between culture and PCR also carries practical weight for diagnostic microbiology. Culture can fail for many reasons: prior antibiotic exposure, which the study tracked among its participants, can render organisms non-viable on the plate; fastidious growth requirements can stall replication; and low bacterial loads can fall below the detection threshold of plating techniques. PCR, by contrast, needs only fragments of DNA. The fourfold difference in detection rates observed here echoes a broader trend in infectious disease diagnostics, where molecular assays increasingly reveal microbial presence that culture-based methods miss, forcing clinicians and researchers alike to rethink what a positive result means. In the nasopharynx, where colonization is the normal state of affairs in early childhood, that question is particularly thorny, because detecting DNA does not distinguish a thriving pathogen from residual genetic material of a dying population.

Funded by a grant from Tehran University of Medical Sciences and conducted with ethical approval and parental informed consent under the principles of the Declaration of Helsinki, the study adds a carefully documented data point to the global map of pediatric pneumococcal ecology. Its message is twofold. First, molecular methods such as lytA PCR uncover pneumococcal carriage at rates far exceeding culture, and any future surveillance or clinical protocol that relies on culture alone will substantially underestimate the true burden of colonization. Second, the predominance of non-encapsulated strains among PCR-positive children, together with the stronger associations seen in those with underlying conditions, abnormal chest imaging, and prolonged hospitalization, sketches a picture in which the vulnerable airways of sick children host a diverse and largely capsule-free pneumococcal population. As conjugate vaccines continue their global rollout, studies like this one, conducted in the unvaccinated state, will remain essential reference points for understanding what changes, what persists, and what was there all along, invisible to the plate but plain to the polymerase.

Subject of Research: Nasopharyngeal Streptococcus pneumoniae colonization in hospitalized children with respiratory symptoms

Article Title: Nasopharyngeal pneumococcal colonization in children with respiratory symptoms in a pre-pneumococcal vaccine era

Article References: Pourakbari, B., Khalilianfard, A., Hosseinpour Sadeghi, R., Jafari, E., Mahmoudi, S., & Mamishi, S. (2026). Nasopharyngeal pneumococcal colonization in children with respiratory symptoms in a pre-pneumococcal vaccine era. BMC Pediatrics. https://doi.org/10.1186/s12887-026-07765-8

Image Credits: AI Generated

DOI: 10.1186/s12887-026-07765-8

Keywords: Streptococcus pneumoniae, nasopharyngeal colonization, pediatrics, PCR, lytA gene, cpsB gene, non-encapsulated strains, pneumonia, empyema, pneumococcal vaccine, Iran, molecular diagnostics